Overview

Study of Talabostat + Docetaxel Versus Docetaxel in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) After Failure of Platinum-Based Chemotherapy

Status:
Terminated

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

Summary

This Phase 3 study will compare the efficacy of talabostat plus docetaxel to docetaxel plus placebo in patients with Stage IIIB/IV NSCLC who have failed a platinum-based chemotherapy regimen.

Phase:

Phase 3

Details

Lead Sponsor:

Point Therapeutics

Treatments:

Docetaxel